Biotech Capital Market Intelligence 
Alpha Sense BI
MAY 28, 2024
The venture capital landscape continues to test the discipline and diligence of investors and startups alike. Like many other asset classes, venture capital continues to be impacted by lingering macroeconomic factors affecting funding and liquidity prospects. Interest rates are high.
Alpha Sense BI
APRIL 29, 2024
Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alpha Sense BI
FEBRUARY 8, 2023
Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices — as well as their intentions to scale their digital health solutions — to the masses in hopes of securing capital.
Alpha Sense BI
JANUARY 25, 2023
Moderna and BioTech, the pharmaceuticals companies behind the Moderna vaccines for the COVID-19 virus, just announced a new treatment this past December that would greatly reduce the chances of death from melanoma — stirring up substantial interest in investors to funnel capital. a potential cure for skin cancer.
Alpha Sense BI
JANUARY 26, 2024
Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices—as well as their intentions to scale their digital health solutions—to the masses in hopes of securing capital.
Alpha Sense BI
APRIL 19, 2024
On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. AlphaSense is a leading provider of market intelligence , including 10,000+ high-quality content sources from more than 1,500 leading research providers—all in a single platform.
Alpha Sense BI
MARCH 13, 2024
billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).
Expert insights. Personalized for you.
69 
Let's personalize your content